Tarlatamab (Imdelltra)

Mechanism of action

From the NCI Drug Dictionary: A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) fused to one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, tarlatamab binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and the DLL3 antigen found on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells.

Diseases for which it is used

• Small cell lung cancer

History of changes in FDA indication

• 2024-05-16: Granted accelerated approval for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. (Based on DeLLphi-301)

Also known as

• Code name: AMG-757
• Brand name: Imdelltra